Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Highlights from PROSCA 2018: Imaging, biomarkers and genetic testing

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 03.07.18
Views: 1950
Rating:

Prof Noel Clarke, Prof Hardev Pandha, Prof Amit Bahl and Dr Nina Tunariu

Prof Noel Clarke, Prof Hardev Pandha, Dr Nina Tunuriu and Prof Amit Bahl discuss the highlights in prostate cancer imaging, biomarkers and genetic profiling from PROSCA 2018 in Frankfurt.

The panel begin by discussing advances in multi-parametic MRI for prostate cancer diagnosis, including the use in combination with standard biopsies to overcome limitations.

Use of biomarkers to determine surveillance vs. treatment is discussed as an interesting strategy in place of MRIs. In practice, the panel agree that MRIs are here to stay and biomarker strategies are more useful following these.

It is agreed that more evidence is needed to further the debate on when biomarker testing is optimal.

Genetic testing for prostate cancer was another key highlight from PROSCA, with a continued movement towards assessing family history of ovarian and breast cancer with the associated BRCA gene.

The panel discuss that consensus over sequencing of diagnostic, surveillance and late stage imaging and biomarkers is still very much an unmet need in the prostate cancer space.

 

Detection of metastasis : M0
Treatment of primary/metastatic lesions
Therapy choice in newly diagnosed disease

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).

 

Related videos

follow us

War on Cancer 2018


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation